IP Verse

Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate - EP3833335

The patent EP3833335 was granted to Intas Pharmaceuticals on Aug 31, 2022. The application was originally filed on Jul 30, 2020 under application number EP20764155A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3833335

INTAS PHARMACEUTICALS
Application Number
EP20764155A
Filing Date
Jul 30, 2020
Status
Granted And Under Opposition
Jul 29, 2022
Grant Date
Aug 31, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

VIATRIS HEALTHCARE LDAJun 5, 2024ELKINGTON AND FIFEINTERVENTION WITHDRAWN
ELKINGTON AND FIFEMay 30, 2023ELKINGTON AND FIFEWITHDRAWN

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0330532
DESCRIPTIONEP0521471
DESCRIPTIONEP1185274
DESCRIPTIONEP1853249
DESCRIPTIONEP2306982
DESCRIPTIONGB1415295
DESCRIPTIONUS2011311625
DESCRIPTIONUS6277405
DESCRIPTIONUSRE37314E
DESCRIPTIONWO2005034908
DESCRIPTIONWO2005034920
DESCRIPTIONWO2008075320
INTERNATIONAL-SEARCH-REPORTWO2008075320
OPPOSITIONEP0330532
OPPOSITIONUS2002009496
OPPOSITIONUS2005096391
OPPOSITIONUS4895726
OPPOSITIONUS6074670
OPPOSITIONWO2008075320

Non-Patent Literature (NPL) Citations (26) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- CHEW et al., J Pharm Pharmaceut Sci, (20020000), vol. 5, pages 162 - 168
DESCRIPTION- KUMAR et al., IJPSR, (20160000), vol. 7, no. 1, pages 413 - 23
INTERNATIONAL-SEARCH-REPORT- Lokesh Kumar ET AL, "COMBINATIONAL THERAPY OF ROSUVASTATIN CALCIUM AND FENOFIBRATE AS BILAYER TABLET: A POTENTIAL APPROACH TO CONTROL HYPOLIPIDAEMIA", International Journal of Pharmaceutical Sciences and Research, doi:10.13040/IJPSR.0975-8232.7(1).413-28, (20160101), URL: http://ijpsr.com/wp-content/uploads/2016/01/53-Vol.-7-Issue-1-Jan-2016-IJPSR-RA-6127-Paper-53.pdf, XP055674904 [X] 1-19 * abstract * * page 416, column left, lines 8-25 * * figure 8 * [I] 20
OPPOSITION- Anonymous, "Assessment report: Cholib - International non-proprietary name: fenofibrate / simvastatine ", EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH; EMA/CHMP/308856/2013 Committee for Medicinal Products for Human Use (CHMP), (20130627), EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH; EMA/CHMP/308856/2013 Committee for Medicinal Products for Human Use (CHMP), (20240313), XP093140976
OPPOSITION- Anonymous, "CRESTOR (rosuvastatin calcium) tablets", PRESCRIBING INFORMATION, (20180901), pages 1 - 36, XP093186224
OPPOSITION- Anonymous, "LIPIDIL TER 160 MG, APTEOR 160 MG", SUMMARY OF PRODUCT CHARACTERISTICS, (20170201), pages 1 - 9, XP093186230
OPPOSITION- Anonymous, "List of nationally authorised medicinal products - Active substance: fenofibrate", EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH; EMA/353788/2021 Human Medicines Evaluation Division, (20210311), EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH; EMA/353788/2021 Human Medicines Evaluation Division, (20240313), XP093140983
OPPOSITION- Anonymous, "TRICOR (fenofibrate)", PRESCRIBING INFORMATION, (20181101), pages 1 - 19, XP093186227
OPPOSITION- Banker Gilbert S, Rhodes Christophert, "SOLID ORAL DOSAGE FORMS ", Modern Pharmaceutics, CRC Press, (19790101), page 397, XP093186875
OPPOSITION- D38 - Supplement information on D31
OPPOSITION- EMA List of nationally authorised medicinal products fenofibrate - List of nationally authorised medicinal products - PSUSA/00001362/201707
OPPOSITION- Gibaldi Milo, "Gastrointestinal Absorption-—Physicochemical Considerations ", Biopharmaceutics and Clinical Pharmacokinetics, FOURTH EDITION, Lea & Febinger, (19910101), page 51, XP093186860
OPPOSITION- Kumar Lokesh, Kumar M Vijay, Tiwari Gaurav, "COMBINATIONAL THERAPY OF ROSUVASTATIN CALCIUM AND FENOFIBRATE AS BILAYER TABLET: A POTENTIAL APPROACH TO CONTROL HYPOLIPIDAEMIA", International journal of pharmaceutical sciences and research, Society of Pharmaceutical Sciences and Research, Pnachkula (HR), IN, IN , (20160101), ISSN 2320-5148, pages 1 - 11, XP093185374
OPPOSITION- Lachman Leon, Herbert A. Lieberman, Joseph L. Kanig, "Factors Affecting Drug Absorption", The Theory and Practice of Industrial Pharmacy, VARGHESE PUBLISHING HOUSE, (19870101), page 221, XP093186868
OPPOSITION- Lachman Leon, Herbert A. Lieberman, Joseph L. Kanig, "Tablets", The Theory and Practice of Industrial Pharmacy, Lea & Febinger, (19860101), pages 330 - 331, XP093186873
OPPOSITION- Mahato Ram I., Narang Ajit S., Pharmaceutical Dosage Forms and Drug Delivery, 2nd ed., CRC Press, (20120101), pages 322 - 323, XP093199212
OPPOSITION- Pande V. et al, "An Overview on Emerging Trends in Immediate Release Tablet Technologies", Austin Therapeutics, (20160101), vol. 3, no. 1, ISSN 2472-3673, pages 1 - 8, XP093146556
OPPOSITION- Remington, "Dissolution", The Science and Practice of Pharmacy, Nineteenth Edition, Volume 1, Library of Congress, (18850101), page 595, XP093186865
OPPOSITION- Taylor Addison A, Omar Shoheiber, "Adherence to Antihypertensive TherapyWith Fixed-Dose AmlodipineBesylate/Benazepril HCl VersusComparable Component-Based Therapy", Congestive Heart Failure, (20231101), pages 324 - 332, XP093230491
OPPOSITION- Wadke D.A. et al, "Preformulation testing", PHARMACEUTICAL DOSAGE FORMS: TABLETS, vol. 1, Marcel Dekker, (19900101), pages 3 - 26, PHARMACEUTICAL DOSAGE FORMS: TABLETS, vol. 1, XP093186857
OPPOSITION- W.A. Ritschel, A. Bauer-Brandl, "Direkttablettierbare Mischungen", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Edito Cantor Verlag , (20020101), vol. 7, pages 252 - 260, ISBN 978-3-87193-228-1, XP008180046
OPPOSITION- Bangalore Sripal, Shahane Anupama, Parkar Sanobar, Messerli Franz H., "Compliance and fixed-dose combination therapy", Current hypertension reports, GB , (20070701), vol. 9, no. 3, doi:10.1007/s11906-007-0033-3, ISSN 1522-6417, pages 184 - 189, XP093230480
OPPOSITION- MUNOZ A, GUICHARD J P, REGINAULT P, "MICRONISED FENOFIBRATE", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19940101), vol. 110, no. SUPPL., doi:10.1016/0021-9150(94)05375-S, ISSN 0021-9150, pages S45 - S48, XP009023822
OPPOSITION- Sarkar Priyanka et al, "FORMULATION DEVELOPMENT AND EVALUATION OF FENOFIBRATE AND ROSUVASTATIN IN COMBINATION TABLETS AND RELEASE RATE IMPROVEMENT", International Journal of Pharmaceutical Sciences and Research, Society of Pharmaceutical Sciences and Research, IN, IN , (20150901), vol. 6, no. 9, doi:10.13040/IJPSR.0975-8232.6(9).4075-79, ISSN 0975-8232, pages 4075 - 4079, XP093186378
OPPOSITION- Ling Hua et al, "A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations", Cardiology Research, (20130101), vol. 4, no. 2, doi:10.4021/cr270w, ISSN 1923-2829, pages 47 - 55, XP093146566
OPPOSITION- Windriyati Yulias Ninik, Sumirtapura Yeyet Cahyati, Pamudji Jessie Sofia, "Comparative In Vitro and In Vivo Evaluation of Fenofibric Acid as an Antihyperlipidemic Drug", Turkish Journal of Pharmaceutical Sciences, (20200101), vol. 17, no. 2, doi:10.4274/tjps.galenos.2019.27147, ISSN 1304-530X, pages 203 - 210, XP093230471

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents